Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.

Background and purpose Since the FDA approved tissue plasminogen activator (tPA) in 1996 for acute ischemic stroke, few data have been obtained during the postmarketing phase, and applicability in rural hospitals does not exist. We attempt to examine the safety and outcome of intravenous tPA for acu... View More